Technical Articles

Bladder cancer
靶向FGFR3的抗体偶联药物在膀胱癌治疗中的研究进展
Research progress of FGFR3-targeting antibody-drug conjugates in the treatment of bladder cancer
发布时间 2026-02-11
Bladder cancer is a common malignant tumor of the urinary system, and its clinical treatment faces core challenges such as high recurrence rates, significant pathological heterogeneity, and limited treatment options.
View details
  • Cancer
  • FGF R3 (IIIc) Fc Chimera protein
  • Bladder cancer
  • Malignant tumor
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.